The expression and clinical significance of Chymase protein in colorectal cancer tissue

doi:10.3877/cma.j.issn.2095-3224.2018.01.008

Abstract

Abstract:

Objective

To investigate the expression and clinical significance of chymase protein in colorectal cancer tissue.

Methods

135 colorectal cancer patients who underwent radical resection were collected at the Cancer Hospital Chinese Academy of Medical Sciences and the Second Affiliated Hospital of Harbin Medical University between September 2010 and September 2012. The expression of Chymase protein in colorectal cancer tissue was detected by immunohistochemistry, and the relationship between Chymase protein and clinicopathological data and prognosis was analyzed.

Results

The expression of chymase protein in colorectal cancer tissue was lower than that of the adjacent tissues, the difference was of statistically significance (Χ²=4.305, P=0.038). In colorectal cancer tissue, the expression of chymase protein was decreased in distant metastatic patients (P=0.002), the expression of chymase protein was decreased in late N staging (Χ²=54.81, P<0.001), the expression of chymase protein was decreased in Ⅲ+ Ⅳ patients (Χ²=50.84, P<0.001), survival analysis indicated that patients with low expression of chymase protein had poor prognosis (X²=10.501, P=0.001).

Conclusion

Chymase protein may be a molecular target for prognosis of colorectal cancer.

Key words: Colorectal neoplasms, Neoplasm metastasis, Prognosis, Chymase

Jinhua Tao, Jian Cui, Fan Zhang, Jianan Chen, Guiyu Wang, Zheng Liu, Xishan Wang. The expression and clinical significance of Chymase protein in colorectal cancer tissue[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2018, 07(01): 36-41.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2018.01.008

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2018/V07/I01/36

Figures/Tables 6

References 23

[1]	Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017 [J]. CA Cancer J Clin, 2017, 67(1): 7-30.
[2]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[3]	Shaw JA, Graham TA, Stebbing J. Genomic instability in pre-neoplastic colonic lesions [J]. Oncogene, 2013, 32(46): 5331-5332.
[4]	Huang H, Bhat A, Woodnutt G, et al. Targeting the ANGPT-TIE2 pathway in malignancy [J]. Nat Rev Cancer, 2010, 10(8): 575-585.
[5]	O′Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer [J]. N Engl J Med, 2013, 368(2): 161-170.
[6]	Shenoy AK, Fisher RC, Butterworth EA, et al. Transition from colitis to cancer: high Wnt activity sustains the tumor-initiating potential of colon cancer stem cell precursors [J]. Cancer Res, 2012, 72(19): 5091-5100.
[7]	Gurish MF, Austen KF. Developmental origin and functional specialization of mast cell subsets [J]. Immunity, 2012, 37(1): 25-33.
[8]	Buhner S, Schemann M. Mast cell-nerve axis with a focus on the human gut [J]. Biochim Biophys Acta, 2012, 1822(1): 85-92.
[9]	He A, Shi GP. Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases [J]. Curr Pharm Des, 2013, 19(6): 1114-1125.
[10]	Heuston S, Hyland NP. Chymase inhibition as a pharmacological target: a role in inflammatory and functional gastrointestinal disorders? [J]. Br J Pharmacol, 2012, 167(4): 732-740.
[11]	Groschwitz KR, Wu D, Osterfeld H, et al. Chymase mediated intestinal epithelial permeability is regulated by protease activating receptor (PAR)-2/ matrix metalloproteinase (MMP)-2-dependent mechanism [J]. Am J Physiol Gastrointest Liver Physiol, 2013 Jan 10 [Epub ahead of print].
[12]	Cho EY, Choi SC, Lee SH, et al. Nafamostat mesilate attenuates colonic inflammation and mast cell infiltration in the experimental colitis [J]. Int Immunopharmacol, 2011, 11 (4): 412-417.
[13]	Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study [J]. N Eng J Med, 1990, 323: 1228-1233.
[14]	Choi CR, Al Bakir I, Ding NJ, et al. Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study [J]. Gut, 2017, pii: gutjnl-2017-314190.
[15]	Cespedes Feliciano EM, Kroenke CH, Meyerhardt JA, et al. Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study [J]. JAMA Oncol, 2017 Aug 10: e172319. [Epub ahead of print].
[16]	Wimberly AL, Forsyth CB, Khan MW, et al. Ethanol-induced mast cell-mediated inflammation leads to increased susceptibility of intestinal tumorigenesis in the APC Δ468 min mouse model of colon cancer [J]. Alcohol Clin Exp Res, 2013, 37(1): 199-208.
[17]	Schwitalla S, Ziegler PK, Horst D, et al. Loss of p53 in Enterocytes Generates an Inflammatory Microenvironment Enabling Invasion and Lymph Node Metastasis of Carcinogen-Induced Colorectal Tumors [J]. Cancer Cell, 2013, 23(1): 93-106.
[18]	Acikalin MF, Oner U, Topçu I, et al. Tumour angiogenesis and mast cell density in the prognostic assessment of colorectal carcinomas [J]. Dig Liver Dis, 2005, 37(3): 162-169.
[19]	Sinnamon MJ, Carter KJ, Sims LP, et al. A protective role of mast cells in intestinal tumorigenesis [J]. Carcinogenesis, 2008, 29(4): 880-886.
[20]	Mehdawi L, Osman J, Topi G, et al. High tumor mast cell density is associated with longer survival of colon cancer patients [J]. Acta Oncol, 2016, 55(12): 1434-1442.
[21]	Nielsen HJ, Hansen U, Christensen IJ, et al. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue [J]. J Pathol, 1999, 189(4): 487-495.
[22]	Tan SY, Fan Y, Luo HS, et al. Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer [J]. World J Gastroenterol, 2005, 11(8): 1210-1214.
[23]	Gulubova M, Vlaykova T. Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer [J]. J Gastroenterol Hepatol, 2009, 24(7): 1265-1275.

组别	例数	Chymase蛋白表达（例）
组别	例数	低表达	高表达
结直肠癌组织	135	71	64
癌旁组织	135	54	81
Χ²值	?	4.305
P值	?	0.038

组别	例数	Chymase蛋白表达（例）
组别	例数	低表达	高表达
结直肠癌组织	135	71	64
癌旁组织	135	54	81
Χ²值	?	4.305
P值	?	0.038

组别		例数	Chymase蛋白表达（例）		Χ²值	P值
组别		例数	低表达	高表达	Χ²值	P值
性别		?	?	?	1.998	0.157
?	男	61	33	28	?	?
?	女	74	31	43	?	?
年龄		?	?	?	0.681	0.409
?	<65岁	88	44	44	?	?
?	≥65岁	47	20	27	?	?
T分期		?	?	?	0.594	0.441
?	T1-2	14	8	6	?	?
?	T3-4	121	56	65	?	?
N分期		?	?	?	54.81	<0.001
?	N0	78	16	62	?	?
?	N1	43	38	5	?	?
?	N2	14	10	4	?	?
M分期		?	?	?	?	0.002^a
?	M0	127	56	71	?	?
?	M1	8	8	0	?	?
TNM分期		?	?	?	50.84	<0.001
?	Ⅰ＋Ⅱ	75	15	60	?	?
?	Ⅲ＋Ⅳ	60	49	11	?	?
分化程度		?	?	?	2.35	0.125
?	高/中分化	99	43	56	?	?
?	低分化	36	21	15	?	?

组别		例数	Chymase蛋白表达（例）		Χ²值	P值
组别		例数	低表达	高表达	Χ²值	P值
性别		?	?	?	1.998	0.157
?	男	61	33	28	?	?
?	女	74	31	43	?	?
年龄		?	?	?	0.681	0.409
?	<65岁	88	44	44	?	?
?	≥65岁	47	20	27	?	?
T分期		?	?	?	0.594	0.441
?	T1-2	14	8	6	?	?
?	T3-4	121	56	65	?	?
N分期		?	?	?	54.81	<0.001
?	N0	78	16	62	?	?
?	N1	43	38	5	?	?
?	N2	14	10	4	?	?
M分期		?	?	?	?	0.002^a
?	M0	127	56	71	?	?
?	M1	8	8	0	?	?
TNM分期		?	?	?	50.84	<0.001
?	Ⅰ＋Ⅱ	75	15	60	?	?
?	Ⅲ＋Ⅳ	60	49	11	?	?
分化程度		?	?	?	2.35	0.125
?	高/中分化	99	43	56	?	?
?	低分化	36	21	15	?	?

组别		估量	标准误	均数		?
				95%可信区间		X²值	P值
				下线	上线	?	?
Chymase		?	?	?	?	10.501	0.001
?	低表达	80.420	1.610	77.264	83.576	?	?
?	高表达	70.207	2.653	65.007	75.407	?	?
T分期		?	?	?	?	4.033	0.045
?	T1-2	84.357	2.222	80.001	88.712	?	?
?	T3-4	73.929	1.794	70.413	77.446	?	?
N分期		?	?	?	?	39.196	0.000
?	N0	83.226	1.258	80.760	85.692	?	?
?	N1	62.573	2.768	58.147	67.998	?	?
?	N2	60.357	0.925	57.544	62.170	?	?
M分期		?	?	?	?	7.362	0.007
?	M0	76.642	1.605	73.497	79.787	?	?
?	M1	59.427	7.378	44.965	73.889	?	?
TNM分期		?	?	?	?	31.851	0.000
?	Ⅰ＋Ⅱ	83.813	1.112	81.634	85.993	?	?
?	Ⅲ＋Ⅳ	65.239	2.630	60.083	70.394	?	?
分化		?	?	?	?	8.363	0.004
?	高/中分化	78.705	1.637	75.496	81.914	?	?
?	低分化	67.238	3.430	60.515	73.960	?	?

Please choose a citation manager

Content to export